Nxera Pharma Partner Neurocrine Gets FDA IND Acceptance for Alzheimer's Drug
Nxera Pharma's partner Neurocrine Biosciences has received FDA IND acceptance for a Phase 2 trial of NBI-1117567 in Alzheimer's-related cognitive impairment, triggering a $10 million milestone payment to Nxera. The programme originated from Nxera's drug discovery collaboration with Neurocrine.